Tetraphase Pharma (TTPH) Tops Q3 EPS by 16c

Tetraphase Pharma (NASDAQ: TTPH) reported Q3 EPS of ($0.49), $0.16 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $3.2 million.

For earnings history and earnings-related data on Tetraphase Pharma (TTPH) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c